Clinical study of pharmacodynamic drug interaction on the management of hyperlipidemic disease

Author(s): Clement Atlee W.*, Vasudevan M.

Abstract

This study was designed to investigate the pharmacodynamic interaction of co-administration of ezetimibe and omega-3-fatty acids on lipoproteins of mixed dyslipidemia in human subjects. Human male subjects were induced hyperlipidemia and they were divided into 4groups of 24 subjects in each group. The inclusion criteria were mixed dyslipidemia with a high triglyceride level (200-499mgper100ml) and a total cholesterol level more than 200mg per 100ml. Present study was conducted on dyslipidemic subjects receiving ezetimibe (10mg) alone, omega-3-fatty acids(4g) alone and combination of ezetimibe (10mg) and omega-3-fattyacids (4g) daily for 90days. After 90days treatment, (Tc, LDL ) was found decreased, Tg level reduced significantly and HDL level increased in the combination therapy ( ezetimibe and omega-3-fattyacids) than their mono therapies. From the result it was concluded that combination therapy of these two may be considered as an optimal treatment option for mixed dyslipidemia.

Share this article

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.